Stereotaxis Inc (STXS) Stock Forecast & Price Target

Stereotaxis Inc is poised for significant growth, with forecasted revenue increases across its segments, predicting a rise to $43 million in Systems, $12 million in Disposables, and $31 million in Royalty streams by FY26E. The company demonstrated strong financial performance with a 95% year-over-year revenue increase to $8.8 million in Q2, driven primarily by heightened demand for its catheter products and a strategic focus on expanding robotic utilization through new product launches. Furthermore, Stereotaxis's successful regulatory advancements and reaffirmation of double-digit revenue growth for 2025 highlight the company's potential for enhanced operational scale and market penetration, particularly with the introduction of its next-generation robotic systems.

Stereotaxis Inc. reported operating expenses of $8.6 million, with adjusted operating expenses declining to $6.0 million from $6.8 million the previous year, signaling some cost control but also highlighting a persistent net loss of $3.8 million. Key risks affecting the company's financial outlook include delays in product approvals, ongoing supply issues with current catheters, changes in reimbursement rates, and competition from alternative technologies, all of which could lead to significant revenue shortfalls. Additionally, with only two years of cash runway remaining, the need for further financing poses an additional risk to Stereotaxis’s operational viability and ability to achieve long-term growth.